HomeCallsNSF-DFG Lead Agency Opportunity in Molecular and Cellular Biology (NSF-DFG MolCellBio)

NSF-DFG Lead Agency Opportunity in Molecular and Cellular Biology (NSF-DFG MolCellBio)

Deadline: from 3 January 2022 on a continuous base Programme calls

To facilitate the support of collaborative work between US researchers and their German counterparts, the Division of Molecular and Cellular Bioscience (BIO/MCB) at NSF and the Division of Molecular and Organismal Biology and Agriculture (MOBA) at the DFG announce a Lead Agency activity in the area of molecular and cell biology.

US-German collaborations are invited to submit joint proposals in the areas covered by BIO/MCB and the DFG’s review board 201 “Basic Research in Biology and Medicine”. The proposals should focus on basic research at a molecular, subcellular or cellular level, including theoretical approaches. Proposals encompassing tissues, organs or whole animals cannot be considered. Research in the area of plant sciences, microbiology, immunology and neurosciences is also excluded. Proposals must provide a clear rationale for the need for a US-German collaboration, including the unique expertise and synergy that the collaborating groups will bring to the project.

Proposals may be submitted to either NSF or DFG. The prospective investigators should discuss within their research team where they believe the largest portion of the research lies and agree on a Lead Agency (either NSF or DFG). The proposers identify the Lead Agency, develop a joint proposal in accordance with the chosen Lead Agency’s standard rules and submit it to the Lead Agency following its submission procedures.

If DFG is the Lead Agency, proposals must be submitted via elan, the DFG’s electronic proposal processing system. Information on submitting proposals to the NSF, can be found in the Dear Colleague Letter NSF 22-015

Proposals can be submitted from 3 January 2022 on a continuous base. There is no deadline for submission to either agency.

Source: German Research Foundation Editor by Mirjam Buse, VDI Technologiezentrum GmbH Countries / organization: USA Topic: Funding Life Sciences

An Initiative of the


About us